ArticleFrontiers in neurology
Gut microbiota 16S rRNA profiling with plasma and urine metabolomics in vestibular migraine.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vestibular migraine (VM) pathophysiology remains unclear, with research often extrapolating from migraine (M) studies. The microbiota-gut-brain axis represents a novel avenue for exploring VM mechanisms and treatments. This study aimed to compare gut microbiota, plasma and urine metabolome alterations among VM patients, M patients, and healthy controls (Hcs). Methods: A cross-sectional study recruited 15 VM patients, 15 M patients, and 15 age-/gender-matched Hcs (April-September 2024) from a tertiary hospital. Final analysis included 10 VM, 15 M, and 15 Hc participants. All underwent fecal 16S rRNA gene sequencing, plasma and urine metabolomics. Demographic and clinical data were collected. Results: Gut microbiota alpha/beta diversity showed no significant inter-group differences. At the phylum level, Verrucomicrobiota and Chloroflexi were reduced in VM vs. M. Genus-level analysis revealed trends (e.g., decreased Conclusions: In this exploratory multi-omics study, VM patients showed distinct gut microbiota composition compared to M and HC, particularly at the genus level. Plasma metabolomics revealed alterations in pyruvate and amino acid metabolism pathways, suggesting possible energy metabolism disturbances in VM. Urine metabolomics highlighted the tyrosine metabolism pathway, with norepinephrine emerging as a metabolite of interest. These preliminary findings point to potential involvement of gut dysbiosis, metabolic perturbations, and neurotransmitter-related pathways in VM pathophysiology, providing a foundation for hypothesis-driven research. Given the exploratory nature of this study, these observations require validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.